Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence

Prof Kevin Harrington - Institute of Cancer Research, London, UK
Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )
2 Jun 2014

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
2 Jun 2014

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA
Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )
2 Jun 2014

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain
Regorafenib shows early promise in colorectal candidates unable to undergo chemo ( Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain )
2 Jun 2014

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany
Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )
2 Jun 2014

Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

Prof Thomas Powles - Barts Health, London, UK
Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer ( Prof Thomas Powles - Barts Health, London, UK )
2 Jun 2014

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France
Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )
2 Jun 2014

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Dr Edith Perez - Mayo Clinic, Rochester, USA
Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )
1 Jun 2014

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain
Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer ( Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain )
1 Jun 2014

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Prof Franco Cavalli, Prof Gordon McVie
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )
1 Jun 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2014

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Dr Alan Venook; Prof Gordon McVie
First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer ( Dr Alan Venook; Prof Gordon McVie )
1 Jun 2014